AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, EMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB,AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDIC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
February 24, 2016
End Date
March 31, 2022
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
February 24, 2016
End Date
March 31, 2022